StockWatch
·
PHARMA & BIOTECH · BSE 532637 · BANK LOAN DEFAULT

Mangalam Drugs re-discloses ₹15.57 Cr bank default — overdue is now a third of its market cap

Bank of Maharashtra (₹9.51 Cr) and Bank of Baroda (₹6.06 Cr) cash-credit accounts overdue since October 2025, against a market cap of ≈₹45 Cr and five straight loss quarters.

MANGALAMMangalam Drugs & Organics Ltd16 Nov 2026 · 4 min read
Last close

₹28.50

Nov 16 — filing hit after close

Size tier

MICRO-CAP

by market cap ≈ ₹45.1 Cr

Amount overdue

₹15.57 Cr

>30 days, as on Nov 15

Overdue vs market cap

≈35%

₹15.57 Cr of ₹45.1 Cr

From 52-week high

−54.4%

high ₹62.50 (Nov 2025)

Q2 FY27 net loss

₹7.21 Cr fifth straight loss quarter in the disclosed window

At 15:42 IST on November 16 — twelve minutes after the market closed — Mangalam Drugs & Organics filed a disclosure under Regulation 30, Para A(6) of Schedule III of SEBI's listing regulations: the company has defaulted on loan obligations to Bank of Maharashtra (₹951.19 lakh, i.e. ₹9.51 crore) and Bank of Baroda (₹606.08 lakh, i.e. ₹6.06 crore), with the amounts overdue for more than 30 days as on November 15, 2026. The combined ₹15.57 crore sits against a market capitalisation of roughly ₹45.1 crore (1.58 crore shares × ₹28.50) — about 35% of what the entire equity is worth at the last close. An identical filing had been submitted three minutes earlier at 15:39; the two are duplicates of the same disclosure.

The filing

A subsequent intimation, but not merely a repeat: the Nov 5 results filing disclosed a Bank of Baroda SARFAESI Act Section 13(2) demand notice and an auditors' emphasis-of-matter flagging material uncertainty on going concern (conclusion unmodified), both new since the October 16 re-disclosure.

credit

Default on Bank of Maharashtra and Bank of Baroda cash-credit accounts re-disclosed

The company declared it "has defaulted on its loan obligations to Bank of Baroda and Bank of Maharashtra for a period exceeding 30 days": ₹951.19 lakh overdue on a Bank of Maharashtra cash-credit account (default dated from October 17, 2025) and ₹606.08 lakh on a Bank of Baroda account (from October 20, 2025), as on November 15, 2026. The letter is signed by Chief Financial Officer Jeevan Dalvi and states the filing is further to an earlier letter dated February 16, 2026. The company adds: "We are also making arrangements to pay the overdue amount as soon as possible."

Read:Both default start dates are over a year old, so this is an ongoing situation being periodically re-disclosed, not a fresh event — a similar subsequent disclosure was filed on October 16, 2026. The ₹15.57 crore figure in this filing is only the amount overdue beyond 30 days; the Q2 results filed November 5 disclose total outstanding to these two banks of ₹55.57 crore, which exceeds the company's entire ₹45.1 crore market cap, and record that Bank of Baroda issued a SARFAESI Act Section 13(2) demand notice on September 23, 2026 for ₹26.72 crore.

BSE filing, Nov 16, 2026 — Defaults under Para A sub-paragraph 6 of Schedule III

The mechanics matter here. These are cash-credit (revolving) facilities, and the filing quotes the regulatory definition it is reporting under: for revolving facilities, an entity is in "default" when the outstanding balance remains continuously in excess of the sanctioned limit or drawing power, whichever is lower, for more than thirty days. In plain terms, the company has been drawn beyond what the banks sanctioned on these working-capital accounts, continuously, with default start dates of October 17 and October 20, 2025. Because the filing reached the exchange at 15:39–15:42 IST, after the 15:30 close, Monday's ₹28.50 close does not reflect it — the first session that can price this disclosure is the next one.

The two defaulted accounts, as disclosed on Nov 16, 2026
BankFacilityOverdue (₹ Cr)Default start
Bank of MaharashtraCash credit a/c 603835612469.5117 Oct 2025
Bank of BarodaCash credit a/c 041705000002436.0620 Oct 2025
Total15.57

Filing states the amounts in ₹ lakh (951.19 and 606.08) as on 15/11/2026; converted to ₹ crore here. Source: BSE filing, Nov 16, 2026.

The P&L behind it

Five straight loss quarters, interest of ₹19.7 Cr over the window

₹ Cr, quarterly consolidated revenue
029.6459.2888.9249.54Q2 FY26Net loss 7.35 · Int 5.0358.49Q3 FY26Net loss 9.84 · Int 4.0567.29Q4 FY26Net loss 13.42 · Int 3.0857.12Q1 FY27Net loss 7.64 · Int 3.6879.39Q2 FY27Net loss 7.21 · Int 3.89
Consolidated quarterly revenue with net loss and interest expense in the sub-labels, ₹ crore. All five quarters in the window are losses. Source: exchange filings.

The Q2 FY27 results, filed on November 5, show consolidated revenue of ₹79.39 crore against expenditure of ₹88.55 crore — a net loss of ₹7.21 crore, the fifth consecutive loss quarter in the data available. Across those five quarters the cumulative consolidated net loss is ₹45.4 crore — almost exactly the company's current market capitalisation — and the interest expense alone totals ₹19.7 crore. The one genuinely improving line is the top line: Q2 FY27 revenue of ₹79.39 crore is up 60.2% on the ₹49.54 crore reported in Q2 FY26, and it is the highest quarterly revenue in the window. The business is selling more; it is not yet selling profitably enough to cover its costs, of which interest is a material part — which is consistent with working-capital accounts running beyond sanctioned limits.

The tape

How the stock has traded into this

₹, daily close (adjusted)
25.8128.7631.7134.6537.628.508-2009-1010-0510-2711-16Prior default re-disclosure · −1.6%Q2 results (after close) · −6.0% next dayDefault re-disclosed after close
Mangalam Drugs (BSE 532637), split/bonus-adjusted daily closes, last 60 sessions. Source: exchange price data.

The stock closed Monday at ₹28.50, down 54.4% from its 52-week adjusted high of ₹62.50 (November 2025) and 25.0% above its 52-week low of ₹22.80 (December 2025). The market's handling of the earlier disclosures is instructive: the October 16 subsequent default filing, which landed during market hours, cost just 1.6% on the day — while the Q2 results filed after close on November 5 were followed by a 6.0% fall the next session. Shareholding offers little cushion: promoters hold 35.65% (56.43 lakh of 1.58 crore shares, unchanged between the June and September quarters), while FII and DII holdings are 17,505 and 306 shares respectively — effectively no institutional presence. This suggests any re-pricing of the November 16 filing will be driven entirely by retail flow in a stock that traded about 20,000 shares on Monday.

What to watch

The filings that would change this picture

  • Next session's reaction

    The filing reached the exchange after Monday's close; the first session that can price it is the next one. The October 16 re-disclosure moved the stock only −1.6% — whether the market treats the November update the same way is the immediate read.

  • Repayment intimation

    The company states it is "making arrangements to pay the overdue amount as soon as possible." A filing confirming regularisation of either cash-credit account would directly shrink the ₹15.57 crore figure; a further subsequent disclosure with a larger number would do the opposite.

  • Q3 FY27 results

    Whether the 60.2% YoY revenue growth of Q2 persists, and whether the loss narrows from ₹7.21 crore. The interest line (₹3.89 crore in Q2) is the direct link between the P&L and the defaulted working-capital accounts.

  • Any lender-side development

    The disclosures are not entirely company-side: the November 5 results already record a SARFAESI Act Section 13(2) demand notice from Bank of Baroda dated September 23, 2026, for ₹26.72 crore. A further bank-side step — a change in default classification, possession of assets, or an auction notice — would be new information, not a repeat.

The November 16 filing does not reveal a new default — the start dates on both accounts are from October 2025, and the company has been making periodic disclosures since at least February 2026. What it does is update the arithmetic: ₹15.57 crore overdue for more than 30 days at a company whose entire market capitalisation is about ₹45.1 crore, whose last five quarters sum to a ₹45.4 crore consolidated loss, and whose interest expense runs at roughly ₹4 crore a quarter. The picture is not static: the November 5 results show total outstanding to the two banks at ₹55.57 crore, a SARFAESI Act Section 13(2) demand notice from Bank of Baroda dated September 23, 2026 for ₹26.72 crore, and an auditors' limited review opinion flagging material uncertainty over the company's ability to continue as a going concern.

The offsetting fact in the data is revenue: ₹79.39 crore in Q2 FY27, the best quarter in the window and up 60.2% year on year. The open question — which only future filings can answer — is whether that growth converts into enough cash to regularise the working-capital accounts before the overdue figure grows again. Investors tracking the name have a clear, dated trail of disclosures to follow.

Informational and educational content only. Not investment advice.